Gene therapy plus Keytruda for advanced stomach or esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced stomach, gastroesophageal junction, or esophageal cancer that can be injected into with a needle, with a tumor at least 1 cm in size.
- Your tumor must have been tested for PD-L1 (a protein affecting immune response), and your doctor should know your score.
- If your PD-L1 score is above 1: you must have already tried at least one line of standard treatment that included an immunotherapy drug (a PD-1 or PD-L1 inhibitor), and your cancer must have progressed during or within 3 months of finishing that treatment.
- If your PD-L1 score is below 1: you must NOT have had prior immunotherapy, but you must have received at least one line of chemotherapy or other standard therapy for advanced disease.
- You cannot have an active autoimmune disease that needed strong immune-suppressing drugs in the last 2 years, cannot be on high-dose steroids (more than 20 mg prednisone daily) within the last week, and cannot have had severe immune side effects from prior immunotherapy.
- No active brain metastases, no uncontrolled infections, no HIV/hepatitis B or C, no other progressing cancer within 3 years, and no organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This trial tests a new treatment that combines a virus designed to deliver a gene (endostatin) directly into tumors with an immunotherapy drug. It is for people with advanced head and neck cancer or esophageal cancer that has returned or spread after prior treatments.
This trial tests combining immunotherapy with radiation for a specific type of stomach or esophagus cancer that has a genetic marker called dMMR/MSI-H. It aims to see if this combination can help people who haven't had any prior treatment.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests a combination of immunotherapy, anti-angiogenic therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't been treated before. It is designed for those whose tumors have low PD-L1 levels.
This trial tests a new combination for advanced stomach cancer: an experimental probiotic (EXL01) plus standard immunotherapy (nivolumab) and chemotherapy (FOLFOX). It is for people whose tumors have a high PD-L1 marker and who have not received prior treatment for advanced disease.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.